Introduction to the Acquisition of Resistance to Targeted Therapy -- Targeting the Tumor Microenvironment to Overcome Resistance to Targeted Therapy -- Current Challenges and Applications of Oncolytic Viruses in Overcoming Resistance to Therapies in Cancer -- Novel Methods to Overcome Acquired Resistance to Immunotherapy -- Therapies to Overcome Multidrug-Resistant Receptors -- Overcoming Resistance to PARP Inhibition -- Novel Methods of Overcoming HER2 Therapy Resistance in Breast Cancer -- Emerging Novel Therapies for Overcoming Resistance to Targeted Therapies -- Targeting Epigenetic Regulators in Cancer to Overcome Resistance to Targeted Therapy -- Nanomedicine and Drug Delivery Systems in Overcoming Resistance to Targeted Therapy -- Index.

Targeted therapies were initially developed to exploit the upregulation and dependence on key oncogenic pathways critical to cancer progression. Additionally, they also presented as a method to overcome chemoresistance by supplementing conventional therapeutic regimens with targeted therapies. However, the development of resistance to these combinatorial approaches has led to the reassessment of currently available therapeutic options to overcome resistance to targeted therapy. This book aims to provide an update on the advancements in the therapeutic arms race between cancer, clinicians and scientists alike to overcome resistance to targeted therapies. Subject experts provide a comprehensive overview of the challenges and solutions to resistance to several conventional targeted therapies in addition to providing a discussion on broad topics including targeting components of the tumor microenvironment, emerging therapeutic options, and novel areas to be explored concerning nanotechnology and the epigenome.